{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:29:02Z","timestamp":1791415742384,"version":"4.3.3"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1016\/j.neuropharm.2006.03.004","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T17:08:55Z","timestamp":1147194535000},"page":"112-120","source":"Crossref","is-referenced-by-count":71,"title":["Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism"],"prefix":"10.1016","volume":"51","author":[{"given":"Ana","family":"Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Mendez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Soto-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Labandeira-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2006.03.004_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ana.410320306","article-title":"Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia","volume":"32","author":"Allen","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib2","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/nrn1434","article-title":"Oxidative stress in neurodegeneration: cause or consequence?","volume":"5","author":"Andersen","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib3","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0306-4522(94)90457-X","article-title":"The angiotensin converting enzyme inhibitors captopril and enalapril inhibit apomorphine-induced oral stereotypy in the rat","volume":"58","author":"Banks","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib4","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ana.410380304","article-title":"Aging, energy, and oxidative stress in neurodegenerative diseases","author":"Beal","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00441-004-0976-5","article-title":"Redox imbalance","volume":"318","author":"Berg","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1476-5381.1996.tb15418.x","article-title":"Ability of angiotensin II to modulate striatal dopamine release via AT1 receptor in vitro and in vivo","volume":"118","author":"Brown","year":"1996","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/0306-4522(82)90033-1","article-title":"Differential distribution of immunoreactive angiotensin and angiotensin-converting enzyme in rat brain","volume":"7","author":"Brownfield","year":"1982","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib8","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1161\/01.RES.0000163631.07205.fb","article-title":"NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease","volume":"96","author":"Cai","year":"2005","journal-title":"Circ. Res."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib9","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1096\/fj.02-0063fje","article-title":"Enalapril and losartan attenuate mitochondrial dysfunction in aged rats","volume":"17","author":"Cavanagh","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mam.2004.02.006","article-title":"Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in ageing","volume":"25","author":"Cavanagh","year":"2004","journal-title":"Mol. Aspects Med."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib11","first-page":"594","article-title":"Biotransformation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in primary cultures of mouse astrocytes","volume":"258","author":"Di Monte","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0014-2999(80)90419-7","article-title":"Captopril given intracerebroventricularly, subcutaneously or by gavage inhibits angiotensin-converting enzyme activity in the rat brain","volume":"68","author":"Evered","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/0891-5849(95)02086-1","article-title":"Different effects of thiol and non-thiol angiotensin-converting enzyme inhibitors on cooper-induced lipid and protein oxidative modification","volume":"20","author":"Fernandes","year":"1996","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib14","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1096\/fj.03-0203fje","article-title":"Synergistic dopaminergic neurotoxicity of MPTP and inflamogen lipopolysaccharide: relevance to the etiology of Parkinson's disease","volume":"17","author":"Gao","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib15","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0014-2999(95)00762-8","article-title":"Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenerative disorders","volume":"297","author":"Ge","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1677\/jme.0.0310359","article-title":"The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms","volume":"31","author":"Gendron","year":"2003","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib17","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1097\/00005344-198900000-00008","article-title":"Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and hoe 288","volume":"14","author":"Gohlke","year":"1989","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib18","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1161\/01.RES.86.5.494","article-title":"NADPH oxidase. Role in cardiovascular biology and disease","volume":"86","author":"Griendling","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib19","first-page":"379","article-title":"Some new, simple and efficient stereological methods and their use in pathological research and diagnosis","volume":"96","author":"Gundersen","year":"1988","journal-title":"APIMS"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jneumeth.2004.02.011","article-title":"High-perfomance liquid chromatography\/tandem mass spectrometry assay for the determination of 1-methyl-4-phenyl pyridium (MPP+) in brtain tissue homogenates","volume":"137","author":"Hows","year":"2004","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib21","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1046\/j.1471-4159.1997.68031304.x","article-title":"Angiotensin-converting enzyme modulates dopamine turnover in the striatum","volume":"68","author":"Jenkins","year":"1997","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1471-4159.1999.0730214.x","article-title":"Effect of chronic angiotensin-converting enzyme inhibition on striatal dopamine content in MPTP-treated mouse","volume":"73","author":"Jenkins","year":"1999","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib23","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1002\/ana.10483","article-title":"Oxidative stress in Parkinson's disease","volume":"53","author":"Jenner","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.brainres.2005.01.066","article-title":"Immunohistochemical study of p47Phox and gp91Phox distributions in rat brain","volume":"1040","author":"Kim","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib25","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.HYP.0000157169.27818.ae","article-title":"Mitochondria-derived reactive oxygen species and vascular MAP kinases. Comparison of Angiotensin II and Diazoxide","volume":"45","author":"Kimura","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0009-8981(94)90259-3","article-title":"Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease","volume":"23","author":"Konings","year":"1994","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1471-4159.2000.0750521.x","article-title":"Protective effect of Harmolol and Harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells","volume":"75","author":"Lee","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib28","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0005-2728(98)00120-0","article-title":"Role of mitochondria in oxidative stress and ageing","volume":"1366","author":"Lenaz","year":"1998","journal-title":"Biochim. Biophys. Acta."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0022-510X(02)00081-3","article-title":"Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson disease","volume":"199","author":"Lin","year":"2002","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib30","doi-asserted-by":"crossref","first-page":"H507","DOI":"10.1152\/ajpheart.2000.278.2.H507","article-title":"Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kinogen-deficient rats","volume":"278","author":"Liu","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib31","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/0006-2952(90)90250-O","article-title":"Protective effects of sulfhydryl-containing angiotensin-converting enzyme inhibitors against free radical injury in endotelial cells","volume":"40","author":"Mak","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0003-2697(78)90586-9","article-title":"A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples","volume":"87","author":"Markwell","year":"1978","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib33","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1357-2725(02)00306-0","article-title":"The brain reenin-angiotensin system: location and physiological roles","volume":"35","author":"McKinley","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0006-8993(93)90902-Y","article-title":"Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rat","volume":"613","author":"Mendelsohn","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3109\/10715769309111600","article-title":"Angiotensin-converting enzyme inhibitors as oxygen free radical scavengers","volume":"19","author":"Mira","year":"1993","journal-title":"Free Radic. Res. Commun."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib36","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/hc3801.095585","article-title":"Are ACE inhibitors a \u201cmagic bullet\u201d against oxidative stress?","volume":"104","author":"M\u00fcnzel","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib37","first-page":"125","article-title":"Free radical scavenging properties of alecepril metabolites and Lisinopril","volume":"196","author":"Noda","year":"1997","journal-title":"Res. Commun. Mol. Pathol. Pharmacol."},{"issue":"RC111","key":"10.1016\/j.neuropharm.2006.03.004_bib38","first-page":"1","article-title":"Induction and activation by Zinc of NADH oxidase in cultured cortical neurons and astrocytes","volume":"20","author":"Noh","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib39","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00019052-199808000-00009","article-title":"Experimental developments in movement disorders: uptake on proposed free radical mechanisms","volume":"11","author":"Przedborski","year":"1998","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib40","first-page":"135","article-title":"The parkinsonian toxin MPTP: action and mechanism","volume":"16","author":"Przedborski","year":"2000","journal-title":"Restor. Neurol. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib41","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.1073\/pnas.93.10.4565","article-title":"Role of neuronal nitric oxide in 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity","volume":"93","author":"Przedborski","year":"1996","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib42","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/0006-8993(81)90735-6","article-title":"Immunoreactivity for angiotensin II-like peptide in the human brain","volume":"205","author":"Quinlan","year":"1981","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib43","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","article-title":"The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease","volume":"30","author":"Reardon","year":"2000","journal-title":"Aust. N. Z. J. Med."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib44","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1460-9568.2004.03621.x","article-title":"Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via Angiotensin Type 2 receptors","volume":"20","author":"Rodriguez-Pallares","year":"2004","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib45","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0165-0270(98)00078-8","article-title":"The overall rod performance test in the MPTP-treated-mouse model of parkinsonism","volume":"83","author":"Rozas","year":"1998","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000125015","article-title":"Differential angiotensin converting enzyme inhibition in brain after oral administration of perindopril demonstrated by quantitative in vitro autoradiography","volume":"48","author":"Sakaguchi","year":"1988","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib47","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","article-title":"Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP","volume":"318","author":"Schober","year":"2004","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-8993(03)03364-X","article-title":"NADPH oxidase immunoreactivity in the mouse brain","volume":"998","author":"Serrano","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib49","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1524-6175.2003.02836.x","article-title":"Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice","volume":"5","author":"Sica","year":"2003","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib50","series-title":"Neuropeptides and their Peptidases","first-page":"165","article-title":"Angiotensin I converting enzyme and its role in neuropeptide metabolism","author":"Skidgel","year":"1987"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib51","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/0196-9781(84)90020-2","article-title":"Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase","volume":"5","author":"Skidgel","year":"1984","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib52","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1046\/j.1471-4159.2000.0741605.x","article-title":"Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease","volume":"74","author":"Soto-Otero","year":"2000","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0006-2952(02)01070-5","article-title":"Effects of (\u2212)-nicotine and (\u2212)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease","volume":"64","author":"Soto-Otero","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000139079","article-title":"Comparative free radical scavenging action of angiotensine-converting enzyme inhibitors with and without the sulfhydryl radical","volume":"47","author":"Suzuki","year":"1993","journal-title":"Pharmacology"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib55","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1592\/phco.23.10.1141.32763","article-title":"Pharmacologic blockade of the rennin-angiotensin system: vascular benefits beyond commoly understood pharmacologic actions","volume":"23","author":"Tsikouris","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2006.03.004_bib56","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1523\/JNEUROSCI.1176-04.2004","article-title":"NADPH oxidase contributes to angiotensin II signalling in the nucleus tractus solitarius","volume":"24","author":"Wang","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/CVM-1-1-038","article-title":"Why do antioxidants fail to provide clinical benefit?","volume":"1","author":"Warnholtz","year":"2000","journal-title":"Curr. Control Trials Cardiovasc. Med."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib58","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1524-6175.2005.04648.x","article-title":"Providing end-organ protection with Renin-Angiotensin system inhibition; the evidence so far","volume":"8","author":"Weir","year":"2006","journal-title":"J. Clin. Hypertens."},{"key":"10.1016\/j.neuropharm.2006.03.004_bib59","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0304-3940(00)00853-3","article-title":"Pramipexole inhibits lipid peroxidation and reduces injury in the substantia nigra induced by dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL\/6 mice","volume":"281","author":"Zou","year":"2000","journal-title":"Neurosci. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390806000530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390806000530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T14:09:31Z","timestamp":1655561371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390806000530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["S0028390806000530"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2006.03.004","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}